279 related articles for article (PubMed ID: 33537861)
41. Fluoropyrimidine-associated cardiotoxicity: revisited.
Saif MW; Shah MM; Shah AR
Expert Opin Drug Saf; 2009 Mar; 8(2):191-202. PubMed ID: 19309247
[TBL] [Abstract][Full Text] [Related]
42. Capecitabine Versus Continuous Infusion Fluorouracil for the Treatment of Advanced or Metastatic Colorectal Cancer: a Meta-analysis.
Wu Z; Deng Y
Curr Treat Options Oncol; 2018 Nov; 19(12):77. PubMed ID: 30483908
[TBL] [Abstract][Full Text] [Related]
43. Improving safety of fluoropyrimidine chemotherapy by individualizing treatment based on dihydropyrimidine dehydrogenase activity - Ready for clinical practice?
Meulendijks D; Cats A; Beijnen JH; Schellens JH
Cancer Treat Rev; 2016 Nov; 50():23-34. PubMed ID: 27589829
[TBL] [Abstract][Full Text] [Related]
44. Cardiotoxicity of 5-fluorouracil.
Alter P; Herzum M; Soufi M; Schaefer JR; Maisch B
Cardiovasc Hematol Agents Med Chem; 2006 Jan; 4(1):1-5. PubMed ID: 16529545
[TBL] [Abstract][Full Text] [Related]
45. Bolus 5-Fluorouracil as an alternative modality to infusion 5-Fluorouracil in a patient with rectal cancer and capecitabine-induced cardiotoxicity.
Shaib W; Lee V; Saif MW
In Vivo; 2009; 23(5):821-6. PubMed ID: 19779118
[TBL] [Abstract][Full Text] [Related]
46. 5-fluorouracil induced cardiotoxicity: review of the literature.
Sorrentino MF; Kim J; Foderaro AE; Truesdell AG
Cardiol J; 2012; 19(5):453-8. PubMed ID: 23042307
[TBL] [Abstract][Full Text] [Related]
47. A Case of 5-Fluorouracil-Induced Cardiac Arrest.
Ray JC; Cho P; Dragon M; Graham CG
J Emerg Med; 2016 Jan; 50(1):e1-6. PubMed ID: 26482827
[TBL] [Abstract][Full Text] [Related]
48. Cardiotoxicity of Fluoropyrimidines: Epidemiology, Mechanisms, Diagnosis, and Management.
Jurczyk M; Król M; Midro A; Kurnik-Łucka M; Poniatowski A; Gil K
J Clin Med; 2021 Sep; 10(19):. PubMed ID: 34640443
[TBL] [Abstract][Full Text] [Related]
49. [Cardiotoxicity of 5-fluorouracil].
Teixeira L; Barry S; Debourdeau P; Cohen A; Tournigand C
Bull Cancer; 2004 Nov; 91 Suppl 3():154-8. PubMed ID: 15899622
[TBL] [Abstract][Full Text] [Related]
50. Risk Factors of Fluoropyrimidine Induced Cardiotoxicity among Cancer Patients: A Systematic Review and Meta-analysis.
Li C; Ngorsuraches S; Chou C; Chen L; Qian J
Crit Rev Oncol Hematol; 2021 Jun; 162():103346. PubMed ID: 33930532
[TBL] [Abstract][Full Text] [Related]
51. Cardiotoxicity following different doses and schedules of 5-fluorouracil administration for malignancy -- a survey of 427 patients.
Tsavaris N; Kosmas C; Vadiaka M; Efremidis M; Zinelis A; Beldecos D; Sakelariou D; Koufos C; Stamatelos G
Med Sci Monit; 2002 Jun; 8(6):PI51-7. PubMed ID: 12070449
[TBL] [Abstract][Full Text] [Related]
52. Cardiotoxicity in cancer patients treated with 5-fluorouracil or capecitabine: a systematic review of incidence, manifestations and predisposing factors.
Polk A; Vaage-Nilsen M; Vistisen K; Nielsen DL
Cancer Treat Rev; 2013 Dec; 39(8):974-84. PubMed ID: 23582737
[TBL] [Abstract][Full Text] [Related]
53. Risk factors and prevention of cardiotoxicity induced by 5-fluorouracil or capecitabine.
Jensen SA; Sørensen JB
Cancer Chemother Pharmacol; 2006 Oct; 58(4):487-93. PubMed ID: 16418875
[TBL] [Abstract][Full Text] [Related]
54. A novel outpatient regimen in management of fluoropyrimidine-induced cardiotoxicity.
Kasi A; Gaudel P; Lekkala M; Al-Rajabi R; Saeed A; Sun W; Porter C
J Oncol Pharm Pract; 2023 Dec; 29(8):1951-1956. PubMed ID: 36883259
[TBL] [Abstract][Full Text] [Related]
55. Prophylactic options in patients with 5-fluorouracil-associated cardiotoxicity.
Cianci G; Morelli MF; Cannita K; Morese R; Ricevuto E; Di Rocco ZC; Porzio G; Lanfiuti Baldi P; Ficorella C
Br J Cancer; 2003 May; 88(10):1507-9. PubMed ID: 12771913
[TBL] [Abstract][Full Text] [Related]
56. FDA Approval: Uridine Triacetate for the Treatment of Patients Following Fluorouracil or Capecitabine Overdose or Exhibiting Early-Onset Severe Toxicities Following Administration of These Drugs.
Ison G; Beaver JA; McGuinn WD; Palmby TR; Dinin J; Charlab R; Marathe A; Jin R; Liu Q; Chen XH; Ysern X; Stephens O; Bai G; Wang Y; Dorff SE; Cheng J; Tang S; Sridhara R; Pierce W; McKee AE; Ibrahim A; Kim G; Pazdur R
Clin Cancer Res; 2016 Sep; 22(18):4545-9. PubMed ID: 27401247
[TBL] [Abstract][Full Text] [Related]
57. [Cardiotoxicity of 5-fluorouracil. Spasm or direct myocardial toxicity?].
Thyss A; Falewee MN; Leborgne L; Viens P; Schneider M; Demard F
Bull Cancer; 1987; 74(4):381-5. PubMed ID: 3663962
[TBL] [Abstract][Full Text] [Related]
58. The need for routine monitoring of cardiac function in patients receiving 5-fluorouracil infusion.
Francis N
Clin J Oncol Nurs; 2014 Jun; 18(3):360-2. PubMed ID: 24867118
[TBL] [Abstract][Full Text] [Related]
59. Severe sequence-specific toxicity when capecitabine is given after Fluorouracil and leucovorin.
Hennig IM; Naik JD; Brown S; Szubert A; Anthoney DA; Jackson DP; Melcher AM; Crawford SM; Bradley C; Brown JM; Seymour MT
J Clin Oncol; 2008 Jul; 26(20):3411-7. PubMed ID: 18612156
[TBL] [Abstract][Full Text] [Related]
60. ST-Segment Elevation Myocardial Infarction Caused by 5-Fluorouracil-Related Cardiotoxicity.
Balaji N; Dixit P; Adams AM; Faiz F; Ngwainmbi D; Henry G; Ghasemzadeh N
Cureus; 2024 Jan; 16(1):e52864. PubMed ID: 38406077
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
